Global Transdermal Scopolamine Market to Reach $528.5 Million by 2027 at a 5.3% CAGR - ResearchAndMarkets.com

DUBLIN–(BUSINESS WIRE)–The “Transdermal Scopolamine: Global Strategic Business Report” report has been added to ResearchAndMarkets.com’s offering.

Global Transdermal Scopolamine Market to Reach $528.5 Million by 2027

In the changed post COVID-19 business landscape, the global market for Transdermal Scopolamine estimated at US$368.7 Million in the year 2020, is projected to reach a revised size of US$528.5 Million by 2027, growing at a CAGR of 5.3% over the analysis period 2020-2027.

The U.S. Market is Estimated at $108.7 Million, While China is Forecast to Grow at 4.9% CAGR

The Transdermal Scopolamine market in the U.S. is estimated at US$108.7 Million in the year 2020. China, the world’s second largest economy, is forecast to reach a projected market size of US$93.2 Million by the year 2027 trailing a CAGR of 4.9% over the analysis period 2020 to 2027. Among the other noteworthy geographic markets are Japan and Canada, each forecast to grow at 5% and 4.2% respectively over the 2020-2027 period. Within Europe, Germany is forecast to grow at approximately 4.4% CAGR.

Select Competitors (Total 41 Featured) –

Alchem International

Alkaloids of Australia

ALZA Corporation

Baxter International Inc.

Caleb Pharmaceuticals Inc

Centroflora-Cms

Fine Chemicals Corporation

GlaxoSmithKline Plc

Myungmoon Pharma Co. Ltd.

Novartis AG

Perrigo Co. Plc

Phytex Australia

Key Topics Covered:

I. METHODOLOGY

II. EXECUTIVE SUMMARY

1. MARKET OVERVIEW

Influencer Market Insights

World Market Trajectories

Transdermal Scopolamine – Global Key Competitors Percentage Market Share in 2022 (E)

Impact of Covid-19 and a Looming Global Recession

Competitive Market Presence – Strong/Active/Niche/Trivial for Players Worldwide in 2022 (E)

2. FOCUS ON SELECT PLAYERS

3. MARKET TRENDS & DRIVERS

4. GLOBAL MARKET PERSPECTIVE

III. MARKET ANALYSIS

IV. COMPETITION

Companies Mentioned